Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

RhoB antibody alters retinal vascularization in models of murine retinopathy.

Almonte-Baldonado R, Bravo-Nuevo A, Gerald D, Benjamin LE, Prendergast GC, Laury-Kleintop LD.

J Cell Biochem. 2018 Dec 9. doi: 10.1002/jcb.28213. [Epub ahead of print]

PMID:
30536763
2.

Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.

Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP.

Eur J Med Chem. 2018 Nov 14;162:455-464. doi: 10.1016/j.ejmech.2018.11.010. [Epub ahead of print]

PMID:
30469041
3.

Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis.

Thomas S, Hoxha K, Alexander W, Gilligan J, Dilbarova R, Whittaker K, Kossenkov A, Prendergast GC, Mullin JM.

J Cell Biochem. 2018 Sep 30. doi: 10.1002/jcb.27716. [Epub ahead of print]

PMID:
30269357
4.

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR.

Clin Cancer Res. 2018 Sep 28. doi: 10.1158/1078-0432.CCR-18-0814. [Epub ahead of print]

PMID:
30266763
5.

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer.

Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC.

Front Oncol. 2018 Sep 11;8:370. doi: 10.3389/fonc.2018.00370. eCollection 2018. Review.

6.

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.

Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC.

Semin Immunopathol. 2018 Sep 10. doi: 10.1007/s00281-018-0702-0. [Epub ahead of print] Review.

PMID:
30203227
7.

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2.

Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR.

J Am Coll Surg. 2018 Apr;226(4):596-603. doi: 10.1016/j.jamcollsurg.2017.12.052. Epub 2018 Feb 7.

8.

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.

Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ.

Int Rev Cell Mol Biol. 2018;336:175-203. doi: 10.1016/bs.ircmb.2017.07.004. Epub 2017 Sep 21. Review.

9.

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ.

Trends Cancer. 2018 Jan;4(1):38-58. doi: 10.1016/j.trecan.2017.11.005. Epub 2017 Dec 21. Review.

10.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

PMID:
29358169
11.

Discovery of IDO1 Inhibitors: From Bench to Bedside.

Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ.

Cancer Res. 2017 Dec 15;77(24):6795-6811. doi: 10.1158/0008-5472.CAN-17-2285. Review.

12.

Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2.

Jusof FF, Bakmiwewa SM, Weiser S, Too LK, Metz R, Prendergast GC, Fraser ST, Hunt NH, Ball HJ.

Int J Tryptophan Res. 2017 Oct 9;10:1178646917735098. doi: 10.1177/1178646917735098. eCollection 2017.

13.

RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Mandik-Nayak L, DuHadaway JB, Mulgrew J, Pigott E, Manley K, Sedano S, Prendergast GC, Laury-Kleintop LD.

Dis Model Mech. 2017 Nov 1;10(11):1313-1322. doi: 10.1242/dmm.029835. Epub 2017 Sep 7.

14.

The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.

Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC.

Cancer Res. 2017 Apr 15;77(8):1783-1812. doi: 10.1158/0008-5472.CAN-16-2929. Epub 2017 Mar 14. Review.

15.

Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Merlo LMF, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L.

Clin Immunol. 2017 Jun;179:8-16. doi: 10.1016/j.clim.2017.01.016. Epub 2017 Feb 20.

16.

A Milestone Review on How Macrophages Affect Tumor Growth.

Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C.

Cancer Res. 2016 Nov 15;76(22):6439-6442. doi: 10.1158/0008-5472.CAN-16-2631. No abstract available.

17.

IDO1 is an Integral Mediator of Inflammatory Neovascularization.

Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ.

EBioMedicine. 2016 Dec;14:74-82. doi: 10.1016/j.ebiom.2016.11.013. Epub 2016 Nov 9.

18.

Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea.

Kutner T, Kunkel E, Wang Y, George K, Zeger EL, Ali ZA, Prendergast GC, Gilman PB, Wallon UM.

Support Care Cancer. 2017 Feb;25(2):581-587. doi: 10.1007/s00520-016-3442-5. Epub 2016 Oct 12.

PMID:
27734152
19.

IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L.

J Immunol. 2016 Jun 1;196(11):4487-97. doi: 10.4049/jimmunol.1600141. Epub 2016 Apr 25.

20.

BIN1 regulates BACE1 intracellular trafficking and amyloid-β production.

Miyagawa T, Ebinuma I, Morohashi Y, Hori Y, Young Chang M, Hattori H, Maehara T, Yokoshima S, Fukuyama T, Tsuji S, Iwatsubo T, Prendergast GC, Tomita T.

Hum Mol Genet. 2016 Jul 15;25(14):2948-2958. Epub 2016 May 14.

PMID:
27179792
21.

Cancer Vaccines: A Brief Overview.

Thomas S, Prendergast GC.

Methods Mol Biol. 2016;1403:755-61. doi: 10.1007/978-1-4939-3387-7_43. Review.

PMID:
27076165
22.
23.

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.

Messerschmidt JL, Prendergast GC, Messerschmidt GL.

Oncologist. 2016 Feb;21(2):233-43. doi: 10.1634/theoncologist.2015-0282. Epub 2016 Feb 1. Review.

24.

Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal.

Prendergast GC.

Cancer Res. 2016 Jan 1;76(1):3. doi: 10.1158/0008-5472.CAN-15-3239. Epub 2016 Jan 3. No abstract available.

25.

O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ.

Eur J Med Chem. 2016 Jan 27;108:564-576. doi: 10.1016/j.ejmech.2015.12.028. Epub 2015 Dec 17.

26.

Neuroprotective effect of Myo/Nog cells in the stressed retina.

Bravo-Nuevo A, Brandli AA, Gerhart J, Nichols J, Pitts M, Sutera CK, Assali S, Scheinfeld V, Prendergast GC, Stone J, George-Weinstein M.

Exp Eye Res. 2016 May;146:22-5. doi: 10.1016/j.exer.2015.11.023. Epub 2015 Dec 10. Review.

PMID:
26688580
27.

Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function.

Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC.

Dig Dis Sci. 2016 Feb;61(2):423-32. doi: 10.1007/s10620-015-3804-8. Epub 2015 Jul 21.

PMID:
26195312
28.

Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy.

Laury-Kleintop LD, Mulgrew JR, Heletz I, Nedelcoviciu RA, Chang MY, Harris DM, Koch WJ, Schneider MD, Muller AJ, Prendergast GC.

J Cell Biochem. 2015 Nov;116(11):2541-51. doi: 10.1002/jcb.25198.

29.

Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers.

Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S, Veldhoen M, Prendergast GC, Platten M, Bessede A, Guillemin GJ.

PLoS One. 2015 Apr 16;10(4):e0122046. doi: 10.1371/journal.pone.0122046. eCollection 2015.

30.

A perspective on cancer as an abortive autoimmune response to altered-self.

Prendergast GC.

Cancer Res. 2015 Jan 1;75(1):3-4. doi: 10.1158/0008-5472.CAN-14-3532. No abstract available.

31.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

32.

IDO2 in Immunomodulation and Autoimmune Disease.

Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L.

Front Immunol. 2014 Nov 20;5:585. doi: 10.3389/fimmu.2014.00585. eCollection 2014. Review.

33.

Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P.

Nature. 2014 Jul 10;511(7508):184-90. doi: 10.1038/nature13323.

34.

1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L.

Autoimmunity. 2014 Sep;47(6):409-18. doi: 10.3109/08916934.2014.914507. Epub 2014 May 6.

35.

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ.

Cancer Immunol Immunother. 2014 Jul;63(7):721-35. doi: 10.1007/s00262-014-1549-4. Epub 2014 Apr 8. Review.

36.

Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes.

Bravo-Nuevo A, Marcy A, Huang M, Kappler F, Mulgrew J, Laury-Kleintop L, Reichman M, Tobia A, Prendergast GC.

PLoS One. 2014 Feb 27;9(2):e90031. doi: 10.1371/journal.pone.0090031. eCollection 2014.

37.

IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L.

J Immunol. 2014 Mar 1;192(5):2082-2090. doi: 10.4049/jimmunol.1303012. Epub 2014 Jan 31.

38.

IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC.

Int Immunol. 2014 Jul;26(7):357-67. doi: 10.1093/intimm/dxt073. Epub 2014 Jan 8.

39.

The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM.

J Immunol. 2014 Feb 1;192(3):1231-40. doi: 10.4049/jimmunol.1300720. Epub 2014 Jan 3.

40.

RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription.

Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, Rigby AC, Nagy JA, Benjamin LE.

Nat Commun. 2013;4:2824. doi: 10.1038/ncomms3824.

41.

CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL.

Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC.

J Radiat Oncol. 2013 Sep 1;2(3). doi: 10.1007/s13566-013-0111-x.

42.

Specific in situ detection of murine indoleamine 2, 3-dioxygenase.

Thomas S, DuHadaway J, Prendergast GC, Laury-Kleintop L.

J Cell Biochem. 2014 Feb;115(2):391-6. doi: 10.1002/jcb.24674.

43.

AACR Cancer Progress Report 2013.

AACR Cancer Progress Report Writing Committee, Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ.

Clin Cancer Res. 2013 Oct 15;19(20 Suppl):S4-98. doi: 10.1158/1078-0432.CCR-13-2107. Epub 2013 Sep 16. No abstract available.

44.

The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis.

Simionescu-Bankston A, Leoni G, Wang Y, Pham PP, Ramalingam A, DuHadaway JB, Faundez V, Nusrat A, Prendergast GC, Pavlath GK.

Dev Biol. 2013 Oct 1;382(1):160-71. doi: 10.1016/j.ydbio.2013.07.004. Epub 2013 Jul 16.

45.

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC.

Oncoimmunology. 2012 Dec 1;1(9):1460-1468.

46.

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models.

Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, Vandenabeele P.

Cell Death Dis. 2012 Nov 29;3:e437. doi: 10.1038/cddis.2012.176.

47.

RIN3 is a negative regulator of mast cell responses to SCF.

Janson C, Kasahara N, Prendergast GC, Colicelli J.

PLoS One. 2012;7(11):e49615. doi: 10.1371/journal.pone.0049615. Epub 2012 Nov 20.

50.

RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.

Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE.

Cancer Res. 2013 Jan 1;73(1):50-61. doi: 10.1158/0008-5472.CAN-11-3055. Epub 2012 Nov 7.

Supplemental Content

Loading ...
Support Center